Cassava Sciences Inc

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cassava Sciences advances Phase III trial with strong financial footing

Cassava Sciences is progressing well with Phase III trial milestones and financial stability, poised to announce critical trial results by year-end.
While facing challenges in data accuracy and increased expenses, the company's proactive approach and strategic planning present significant growth opportunities.
By focusing on innovation and market transformation, Cassava Sciences is positioned to redefine Alzheimer's disease diagnosis and treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

Cassava Sciences Inc. said Wednesday it is planning a registered direct offering of $200 million of shares, priced at $49 each, or a discount over Tuesday's closing price of $450.29. The company, which is developing a treatment for Alzheimer's disease, said H.C.

Cassava Sciences to offer $200 million of shares priced at $49 each vs. $50.29 at Tuesday's close

AUSTIN, Texas, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced that it has entered into a definitive agreement with several healthcare-focused and other institutional investors for the purchase of 4,081,633 shares of its common stock, at a purchase price per share of $49.00, for gross proceeds of approximately $200.0 million, in a registered direct offering. The closing of the offering is expected to occur on or about February 12, 2021, subject to the satisfaction of customary closing conditions.

Cassava Sciences Announces $200 Million Registered Direct Offering of Common Stock

Cassava (SAVA) provides outline for future study plans on its Alzheimer's disease candidate, simufilam.

Cassava (SAVA) Rises on Late-Stage Alzheimer's Study Plans

Can this company's Alzheimer's disease candidate deliver further gains ahead?

Should You Sell Cassava Sciences Stock Now?

Ocugen, Inc.

Find out what these two red-hot stocks are doing to earn investors' love.

Why Ocugen and Cassava Sciences Stock Led the Nasdaq to All-Time Highs

Cassava Sciences Inc (NASDAQ: SAVA) shares were trading solidly higher Monday on above-average volume in reaction to updates from the company on clinical programs and upcoming catalysts. The Austin, Texas-based biopharma is engaged in the development of therapies for neurodegenerative conditions.

Why Cassava Shares Are Rallying Today

The stock price of Cassava Sciences Inc (NASDAQ: SAVA) is trading at over 15% pre-market as of 9:14 AM ET today. This is why it happened.

SAVA Stock Price Increases Over 15% Pre-Market: Why It Happened

Shares of Cassava Sciences Inc. rallied 18.5% in premarket trading on Monday after the company said it plans to start a double-blind, randomized, placebo-controlled study of its Alzheimer's disease treatment candidate. This kind of trial is considered the gold standard in medical research.

Cassava's stock jumps 18% on plans to initiate late-stage study for Alzheimer's drug

AUSTIN, Texas, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer's disease, today announced significant program progress and expected milestones for 2021.

Cassava Sciences Announces Significant Program Progress and Expected Key Milestones in 2021 for Its Clinical Program in Alzheimer's Disease

Of the stocks with volatile price action this week, perhaps the wildest has been Cassava Science Inc. (NASDAQ: SAVA) — the PreMarket Prep Stock of the Day. The Company: Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease.

PreMarket Prep Stock Of The Day: Cassava Science

Cassava Sciences said Thursday its Alzheimer's treatment showed promise in a six-month study and SAVA stock bolted to a record high. The study is still enrolling patients.

Cassava Bolts To Record High After Alzheimer's Drug Improves Cognition

The stock price of Cassava Sciences Inc (NASDAQ: SAVA) is trading at over 40% pre-market today as of 6:32 AM ET. This is why it happened.

SAVA Stock Price Increases Over 40% Pre-Market: Why It Happened

Investors are betting this underdog will succeed where even the most reputable of biotech firms have failed.

Can This Maverick Biotech Become the Frontrunner in the Fight Against Alzheimer's?

Cassava Sciences Inc (NASDAQ: SAVA) shares rallied over 97% today in the regular and after-hours sessions. What Happened: The upwards movement was an extension from a day ago when shares rose 150% after the company announced the results of an interim analysis of its lead drug candidate for Alzheimer's disease — simufilam.

Why Cassava Sciences Shot Up 97% Today

Anavex Life Sciences

Axsome Therapeutics

Hologic

Moderna

Novavax

Meridian Bioscience

Vaxart

From vaccines to diagnostics, the opportunities in biotechnology are rich for those who do their homework.

Biotech Bonanza: COVID Launches Science at Warp Speed

The stock price of Cassava Sciences Inc (NASDAQ: SAVA) has increased over 45% today. This is why it happened.

SAVA Stock Price Increases Over 45%: Why It Happened

Cassava Sciences (SAVA) stock is on the rise Wednesday after revealing interim results from a recent Alzheimer's disease clinical trial. The post SAVA Stock: 12 Things for Investors to Know About Cassava Sciences as Shares Soar appeared first on InvestorPlace.

SAVA Stock: 12 Things for Investors to Know About Cassava Sciences as Shares Soar

Cassava's (SAVA) Alzheimer's disease candidate, simufilam, improved cognition and behavior scores following six months of treatment in an open-label clinical study.

Cassava (SAVA) Soars on Encouraging Alzheimer's Study Data

The biotech's experimental Alzheimer's treatment could be a game changer.

Why Cassava Sciences Stock Skyrocketed Today

Cassava Sciences (NASDAQ: SAVA) shares are trading higher Tuesday after the company announced results of an interim analysis from an open-label study of simufilam, its lead drug candidate for the treatment of Alzheimer's disease. "Patients' cognition and behavior scores both improved following six months of simufilam treatment, with no safety issues," according to the company.

Why Cassava Sciences Stock Is Surging Higher Today

The stock price of Cassava Sciences Inc (NASDAQ: SAVA) has increased over 150% today. This is why it happened.

SAVA Stock Price Increases Over 150%: Why It Happened

Shares of Cassava Sciences soared as much as 221% Tuesday after the biopharmaceutical company announced upbeat data on its leading drug candidate for the treatment of Alzheimer's disease. The stock price of the Austin, Texas-based company surged toward an almost 10-year high, on track to close to its highest level since June 2011.

Cassava Sciences soars over 200% to 10-year high on positive Alzheimer's treatment data (SAVA)

Shares of Cassava Sciences Inc. more than doubled toward a near 10-year high in very active trading Tuesday, after the company focused on neurodegenerative disease treatments announced upbeat results from a study of its treatment for Alzheimer's disease. The stock shot up 173.6%, enough to pace all gainers trading on major U.S. exchanges, and to put it on track for the highest close since June 2011.

Cassava Sciences stock nearly triples toward a 10-year high after upbeat data on Alzheimer's treatment

Interim analysis of the first 50 patients to complete 6 months of sumifilam treatment came sooner than we expected. The results are nothing short of phenomenal and historic - "Patients' cognition and behavior scores both improved following six months of sumifilam treatment, with no safety issues"

Historic Day In Alzheimer's As Cassava Sciences' Sumifilam Improves, Not Just Stabilizes, Cognition And Is Again Shown Safe

It's been 20 days since we released a report on Cassava Sciences saying it could be the best-performing stock of 2021. The stock has already doubled, but we think this is just the beginning.

News for Cassava Sciences Inc Stock (SAVA)